Can You Repair Hyper Inflamed Lungs?

• Journal Listing
• Prim Care Respir J
• 5.22(1); 2022 Mar
• PMC6442765

Prim Care Respir J. 2022 Mar; 22(i): 101–111.

No room to exhale: the importance of lung hyperinflation in COPD

Mike Thomas

¹Department of Master Care Enquiry, University of Southampton, Southampton, United kingdom

Marc Decramer

^twoRespiratory Partition, University Hospitals, Leuven, Belgium

Denis E O'Donnell

^threeDivision of Respirology, Queen's University and Kingston General Hospital, Kingston, Ontario, Canada

Received 2022 Oct 23; Revised 2022 Dec 19; Accustomed 2022 Dec 22.

Abstract

Patients with chronic obstructive pulmonary disease (COPD) are progressively limited in their ability to undertake normal everyday activities by a combination of exertional dyspnoea and peripheral muscle weakness. COPD is characterised by expiratory flow limitation, resulting in air trapping and lung hyperinflation. Hyperinflation increases acutely nether conditions such as exercise or exacerbations, with an accompanying precipitous increase in the intensity of dyspnoea to distressing and intolerable levels. Air trapping, causing increased lung hyperinflation, tin can be present even in milder COPD during everyday activities. The resulting activity-related dyspnoea leads to a savage screw of action avoidance, physical deconditioning, and reduced quality of life, and has implications for the early development of comorbidities such as cardiovascular disease. Various strategies exist to reduce hyperinflation, notably long-acting bronchodilator handling (via reduction in flow limitation and improved lung emptying) and an exercise plan (via decreased respiratory charge per unit, reducing ventilatory demand), or their combination. Optimal bronchodilation can reduce exertional dyspnoea and increase a patient'due south ability to exercise, and improves the risk of successful outcome of a pulmonary rehabilitation plan. There should be a lower threshold for initiating treatments advisable to the stage of the disease, such as long-acting bronchodilators and an exercise programme for patients with balmy-to-moderate disease who experience persistent dyspnoea.

Keywords: COPD, dyspnoea, exacerbations, exercise, hyperinflation, inspiratory capacity

Introduction

Worldwide, chronic obstructive pulmonary disease (COPD) is estimated to affect 10% of the population aged >xl years.¹ In primary intendance in the Uk, the estimated prevalence of COPD is seven% of those aged ≥45, increasing to 8–9% of those aged ≥65.^two Still, underdiagnosis is a problem, and the true prevalence is likely to be much higher. Using specific screening for COPD, a report amid primary care practices in Canada found a prevalence of 21% amongst those aged over forty.^three COPD is an important cause of mortality and morbidity,⁴ and even patients in the milder stages of disease are at increased take a chance.^five

Many patients with COPD can no longer do the activities they used to practice, or cannot sustain them to the aforementioned extent, because they are limited by respiratory difficulty or dyspnoea.^6–8 Activeness-related dyspnoea is among the earliest and virtually troublesome symptoms of COPD, and it progresses over time to incapacitating levels.⁹ Limitations on activity frequently atomic number 82 to feelings of social isolation and psychological bug and reduce a patient's perceived quality of life, which is further diminished by the resulting inactivity and physical deconditioning.⁶ The mechanisms underlying action limitation and dyspnoea are complex, and the state of affairs is further complicated by the problems of ageing and co-morbidity that are common in patients with COPD.

We performed a review of the electric current medical literature investigating the mechanisms of hyperinflation and its effects on the dyspnoea and activity limitation experienced by patients with COPD. Diverse treatment modalities have been employed to overcome the problem, and the effects of pharmacological treatment on hyperinflation are summarised. The summary of treatment furnishings was based on a literature search of the PubMed database (no date limits) for COPD and terms relating to hyperinflation, narrowed by individual drug name (see Appendix 1, available online at www.thepcrj.org, for consummate search strategy).

Mechanisms underlying exercise limitation in COPD

COPD is a highly heterogeneous condition with many different factors contributing to its pathophysiology, and the relative contribution of these factors varies from patient to patient. The term COPD principally encompasses two conditions — chronic bronchitis and emphysema. Chronic bronchitis is characterised by airways obstruction resulting from inflammation and remodelling of the larger airways, with oedema and increased mucus production.¹⁰ Emphysema is characterised by irreversible impairment to the lung parenchyma and adjacent vasculature. A recent report suggests that obliteration and narrowing of terminal bronchioles may precede the development of subversive emphysema.¹¹ The loss of lung elastic recoil force per unit area reduces the driving pressure for flow during expiration: expiratory catamenia rates are diminished at any given lung book compared with wellness. In improver, the loss of alveolar walls and attachments, which normally assist to maintain airway patency, renders the airways more liable to collapse during expiration. Collectively, these changes give ascent to expiratory flow limitation.

Changes to the elastic properties of the lungs in emphysema alter the balance of forces between the lung (inward recoil) and breast wall (outward recoil), so that the relaxation book of the respiratory system at the cease of quiet expiration (end-expiratory lung book; EELV) is reset to a higher volume than is predicted in health (i.e. static lung hyperinflation). In the presence of expiratory catamenia limitation, the ability to empty the lungs with each breath is critically dependent on the time available for expiration. In many patients with catamenia-limited COPD, expiratory time during spontaneous resting animate is but bereft to allow full lung elimination and gas trapping is the result (Figure one).

Schematic to illustrate how peripheral airway obstacle traps air during expiration in chronic obstructive pulmonary disease (COPD) resulting in hyperinflation. P_L=translung pressure level, Five=ventilation. Reproduced from O'Donnell and Laveneziana⁵⁶ with permission

EELV can increase temporarily and to a variable extent higher up the resting value in situations where expiratory period limitation is suddenly worsened (i.e. bronchospasm or exacerbation) or when ventilatory demand is abruptly increased, such as with exertion, anxiety, or transient hypoxaemia.¹² This is termed 'dynamic lung hyperinflation'. In conditions of increased metabolic demand such every bit exercise, when animate is accelerated, increased gas trapping becomes inevitable. The presence of lung overinflation limits the ability of tidal volume to aggrandize, and ventilation can only be increased by faster breathing, contributing to further hyperinflation in a brutal cycle.

Although not discussed hither, many other factors contribute to limiting a patient's activity in COPD, not to the lowest degree peripheral muscle weakness and deconditioning due to factors such as ageing, poor nutrition, and co-morbidities.^{thirteen–15}

Pressure–volume relationship

From the get-go of an intake of breath after fully emptying the lungs (residual volume, RV) to the cease (full lung capacity, TLC), the relationship between chest wall pressure and lung volume follows an S-shaped bend.¹⁶ Salubrious subjects breathe at around the midpoint of the curve where volume can increase at comfortable pressure. With their larger lung book due to gas trapping, COPD patients breathe above the curve where the animate muscles take to overcome relatively larger 'elastic' forces to achieve the same increase in lung volume during breathing (Figure ii).

Lung volumes at residual and during exercise in healthy subjects and in patients with chronic obstructive pulmonary disease (COPD). In normal lungs, end-expiratory lung volume (EELV) remains relatively abiding during exercise as tidal book tin increase and inspiratory capacity (IC) is maintained. Patients with COPD breathe with a greater EELV and less IC. During practice, as ventilation increases, the increased EELV (dynamic hyperinflation) pushes tidal book closer to total lung chapters (TLC) where expansion is limited by high pressures. IC decreases and breathing becomes and so restricted that patients have to stop activity. RV=residual volume, IRV=inspiratory reserve volume. Reproduced from O'Donnell et al. ^xvi with permission

Sure adaptive responses occur to compensate for chronic hyperinflation, including adaptations of the chest wall and diaphragm shape to accommodate the increased volume, and adaptations of muscle fibres to preserve strength and increment endurance in the confront of chronic intrinsic mechanical loading.¹⁷ Even so, these compensatory mechanisms are quickly overwhelmed when ventilatory demand increases acutely (due east.g. during practise).^{xviii–twenty}

Exercise

Because of the already high operating volumes in COPD, whatever expansion in tidal volume during practice can be gained only by greater forcefulness generation (and contractile try) past the inspiratory muscles (meet Effigy 2). Expiratory flow limitation and the accompanying dynamic hyperinflation strength the contractile units of the inspiratory muscles to operate at a shorter disadvantageous length, which ultimately weakens the muscles. Inflammation and oxidative stress increase the susceptibility of respiratory muscles to contractile dysfunction nether astute inspiratory loading.²¹

Exacerbations of COPD

An acute increment in hyperinflation can likewise occur during exacerbations, and is believed to be an of import correspondent to the characteristic symptom of worsening dyspnoea.^12,22,23 COPD exacerbations differ greatly in their clinical presentation, reflecting differences in patients' clinical characteristics, the presence of co-morbidities such as chronic heart failure, the underlying pathophysiology of COPD, and causative factors.²⁴ Exacerbations involve increased airway inflammation and worsening airway obstruction, in variable contributions. The effectiveness of various non-steroidal treatment modalities in reducing the severity and frequency of exacerbations (bronchodilator drugs, surgery)^25,26 and the differential upshot of bronchodilators and corticosteroids on exacerbations²⁷ suggest that exacerbations can involve worsening airway obstruction in the absenteeism of airway inflammation,¹² assuming that these bronchodilators exercise not exert anti-inflammatory furnishings in patients with COPD in vivo.

Studies in hospitalised patients with astute respiratory failure undergoing mechanical ventilation have shown that severe exacerbations involve a mechanism of critical expiratory flow limitation with lung hyperinflation, with serious mechanical consequences.²⁸ This can cause fatigue or overt failure of the respiratory muscles. Less is known almost the mechanisms behind symptomatic deterioration during balmy-to-moderate exacerbations that are unremarkably encountered in clinical practice, but the underlying physiology is likely to be similar to that of astringent exacerbations.^12,22

Sensory feel of breathlessness in COPD

In weather such every bit do and exacerbation, the drive to breathe is increased only the ability of the respiratory system to respond appropriately is greatly hindered. This disparity between the increased central drive to exhale and the mechanical/muscular response of the respiratory system is termed 'neuromechanical uncoupling' or dissociation. Although patients endeavor to come across the increased ventilatory demand, they cannot increase the tidal book very much (constrained at one stop by increased EELV and at the other by the fact that they are forced to exhale shut to TLC; Effigy 2). With literally no room to breathe despite near-maximal neural drive, patients experience intolerable dyspnoea very speedily.

While COPD patients — in common with healthy subjects — depict their dyspnoea on exercise in terms of increased endeavour and heaviness of breathing, they also draw some unique sensations such as "can't get enough air in" or "unsatisfied inspiratory try" (Effigy three).²⁹ This is somewhat akin to 'air hunger' which can be induced experimentally in healthy volunteers when CO2 loading is combined with mechanical restriction of lung volume expansion.^xxx This suggests that COPD patients are receiving abnormal peripheral neurosensory data from diverse mechanical receptors in the respiratory muscles and chest wall, signalling that respiration is inadequate for the excessive effort expended. The perception of unsatisfied endeavour is rarely reported in salubrious subjects.

Qualitative descriptors of exertional dyspnoea (at the terminate of symptom-limited cycle exercise) of 'unsatisfied inspiration', 'inspiratory difficulty', and 'shallow breathing' were more than common amongst patients with chronic obstructive pulmonary disease (COPD) than in good for you subjects (^*p<0.05). Modified from O'Donnell et al. ²⁹ with permission

The alter in clarification of the awareness from 'piece of work and endeavor' to 1 of 'unsatisfied inspiration' occurs when the drive to breathe continues to increase without a respective increment in lung volume, and the intensity of dyspnoea rises sharply. This inflection point in the human relationship between volume and endeavour during practise, when tidal volume can no longer increase in line with increasing ventilatory bulldoze, is depicted in Effigy iv.^31,32 The relationship between the increase in dyspnoea and the point where tidal book is close to TLC is similar across differing levels of baseline airway obstruction.³²

In a study in hyperinflated subjects with chronic obstructive pulmonary illness (COPD), with increasing animate frequency, tidal volume (VT) expanded to a maximal value of approximately 75% of the concurrent inspiratory capacity (IC) (left). When this plateau in VT/IC occurs, and regardless of baseline differences in lung role, dyspnoea rises sharply to intolerable levels (right). Q=quartile of COPD severity (airflow limitation). Forced expiratory volume in 1 second quartiles were mean 62%, 49%, 39%, and 27% predicted. Modified from O'Donnell et al. ³² with permission)

The perception of unsatisfied inspiration is likely to evoke a powerful fearfulness response that escalates to panic, or respiratory distress.²⁹ In full general, COPD subjects are distinct from healthy subjects in describing their awareness of breathlessness in terms such as 'frightening', 'helpless', and 'awful'.³³ The descriptions of dyspnoea that reflect fear and anxiety become more common with increasing severity of COPD.³⁴ This powerful melancholia dimension of dyspnoea has been highlighted in a recent American Thoracic Society statement.³⁰

Hyperinflation and relationship with COPD progression and co-morbidities

Cantankerous-sectional studies have demonstrated the presence of hyperinflation in milder stages of COPD, including dynamic hyperinflation during everyday activities.^9,35–37 The early stages of hyperinflation and its progression may not be perceived by patients because of adaptive changes that compensate for the mechanical disadvantages (east.g. chest wall reconfiguration to accommodate overextended lungs and partially preserved function of the diaphragm despite operating at shortened musculus fibre length).^twenty,38 Pathological changes in the muscle fibres of the diaphragm may exist evident even in the milder stages of COPD.³⁹

Hyperinflation, physical inactivity, and physical deconditioning may be related to the early development of co-morbidities. Inactivity and musculus wasting are present in the primeval stages of COPD^40–43 and may exist of import for the development of co-morbidities that can too occur in milder stages of COPD.^44,45 For example, subclinical left ventricular dysfunction in milder COPD was found to be especially marked in patients with resting hyperinflation.⁴⁶

The presence of hyperinflation may influence the progression of disease: resting hyperinflation (inspiratory capacity (IC)/TLC ratio <25%) has been associated with increased frequency of COPD exacerbations,⁴⁷ and is an independent predictor of bloodshed in COPD.⁴⁸ Of potential relevance, hyperinflation of the lung (assessed past quantitative computed tomography) was plant to predict a rapid annual decline in forced expiratory book in 1 second (FEV₁) in smokers with normal FEV_i.⁴⁹ If, equally recently shown, near of the reject in lung function occurs in milder disease,^44,50–52 information technology may be hypothesised that some form of early on intervention could forestall progressive functional deterioration and maintain organ function at a college level.

Measurement of hyperinflation in COPD

Hyperinflation is hard to measure with the investigations commonly available in general practice. Relevant measures in COPD are functional residual capacity (the volume of air remaining in the lungs at the end of tidal expiration, an index of hyperinflation), and RV (the book of air remaining in the lungs at the end of a maximal expiration, an alphabetize of air trapping), simply both of these volume measurements require relatively sophisticated equipment (torso plethysmography or spirometers with inert gas analysers).⁵³

IC is often used every bit a surrogate measure of hyperinflation. This is the maximal volume of air that tin be inspired after a quiet breath out, which is the difference betwixt TLC and EELV. IC can be measured by simple spirometry using a closed-circuit organisation.⁵³ Provided TLC remains constant, reduced resting IC indicates the presence of hyperinflation in the setting of expiratory flow limitation.⁵⁴ IC may not ever be a reliable measure in atmospheric condition of severe hyperinflation or over fourth dimension (when TLC changes).^55,56 IC measurements during do reflect the increment in dynamic EELV and are more relevant physiologically with respect to exertional dyspnoea and practise intolerance than resting IC.⁵⁷ A contempo report has shown that critical reduction of the inspiratory reserve volume (IRV; calculated as IC minus tidal volume), an index of 'the room to breathe', is more closely related to dyspnoea intensity during exercise in COPD than is the extent of air trapping per se. ^58,59

Event of treatment

Treatment strategies

A treatment that tin bring about a reduction in EELV (and increase in IRV) should enable a patient to increase tidal volume more than for a given effort, and thus lessen exertional dyspnoea. A treatment that improves expiratory catamenia limitation or decreases ventilatory demand will interrupt the barbarous cycle of faster breathing and worsening hyperinflation. Thus, there is a range of handling strategies^60,61 that may be employed in different settings, from drug treatments and supplemental oxygen for patients with hypoxia or oxygen desaturation available in principal intendance, to assisted ventilation for hospitalised patients and surgical options for those with advanced emphysema.

Treatments that primarily decrease respiratory rate (reducing ventilatory need) and increase ventilation include rehabilitative exercise training (pulmonary rehabilitation) and supplemental oxygen. Assisted ventilation counterbalances the negative furnishings of lung hyperinflation on the respiratory muscles. Handling with bronchodilators primarily reduces flow limitation and improves lung emptying. Lung volume reduction surgery reduces EELV by favourably altering the elastic properties of the remaining lung, thus increasing lung emptying. The different mechanisms past which these interventions operate suggest that combinations would provide additional benefits, an example being the additive benefits shown by the combination of tiotropium (reduced hyperinflation) with supplemental oxygen (reduced ventilatory bulldoze),⁶² and ipratropium bromide or supplemental oxygen with rehabilitation.^63–65 This review will focus on the treatments that are bachelor in the principal care setting, principally pharmacotherapy and practice programmes.

Pulmonary rehabilitation/practise training

Increasing activity levels is a fundamental role of interrupting the downward spiral of inability and premature death for COPD patients.⁶⁶ Pulmonary rehabilitation is a cornerstone in the comprehensive management of patients with COPD, and has recognised benefits for improved exercise endurance, dyspnoea, functional capacity, and quality of life (Table i).⁶⁷ The forcefulness of evidence is reflected in its prominence in global and national COPD direction guidelines.^67–73 Pulmonary rehabilitation is currently the best way to improve quality of life in patients with COPD.^71,74 Comprehensive pulmonary rehabilitation programmes include exercise training, smoking cessation, nutrition counselling, and instruction.⁶⁷

Table one

Benefits of pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD)⁶⁷

Exercise training improves skeletal muscle function and leads to less ventilatory requirement for a given work rate, which in turn may reduce dynamic hyperinflation, thus reducing exertional dyspnoea.⁷⁰ Because practice capacity is express by both skeletal musculus fatigue and exertional dyspnoea due to dynamic hyperinflation, bronchodilator therapy may help amend the effectiveness of exercise preparation by lowering the bulwark of activity-limiting dyspnoea and allowing patients to exercise their peripheral muscles to a greater degree.^lxx,75 Practice guidelines recommend that optimal bronchodilator therapy should exist given prior to exercise training.⁷⁰ Fifty-fifty if a formal exercise programme is not available, patients should be encouraged to undertake regular practice such as walking for xx minutes a day.⁶⁷

Effect of pharmacotherapy on hyperinflation

Show for the furnishings of pharmacotherapy on hyperinflation was gathered using the search strategy shown in Appendix 1 (online at www.thepcrj.org). Single-dose studies were not included.

Bronchodilators

Bronchodilators work by relaxing smoothen muscle tone in the airways, leading to reduced respiratory muscle activity and improvements in ventilatory mechanics.⁷⁶ In addition, reduced abdominal musculus activation and the consequent fall in gastric pressure following bronchodilator therapy may contribute to relieving the load on the respiratory system, similar to the relief provided by non-invasive ventilatory back up.^76–78 Bronchodilators have been associated with reduced airways resistance and elastic loading of the inspiratory muscles during constant work rate exercise.⁷⁹ The lower operating lung volume allows patients to accomplish the required alveolar ventilation during residual and practice at a lower oxygen cost of breathing. Past deflating the lungs, bronchodilators finer improve ventilatory musculus performance resulting in greater tidal volume expansion. Thus, neuromechanical coupling is enhanced and dyspnoea is lessened. Reduction in absolute lung volume results in a delay in the time for end-inspiratory lung volume to reach the minimal dynamic IRV; the mechanical limitation of ventilation is postponed and practise endurance time is prolonged.⁷⁹ With short-interim inhaled bronchodilators, 3 multiple-dose studies reported improvements in lung volume and exercise measures with single or combined treatments (β₂-agonist plus anticholinergic; β₂-agonist plus theophylline).^80–82

Multiple-dose studies that have investigated the furnishings of long-acting bronchodilators on both resting hyperinflation and dynamic hyperinflation during exercise are summarised in Tabular array 2 and Appendix ii (available online at www.thepcrj.org). The results demonstrate improved IC throughout rest and exercise, in clan with numerical or significant improvement in dyspnoea intensity ratings during exercise and increased exercise endurance (Table ii and Appendix two). Many other studies take investigated the furnishings on resting hyperinflation alone, and report improvements measured past IC and volume measurements during treatment with indacaterol,⁸³ formoterol,^84,85 salmeterol,⁸⁶ tiotropium,^55,87–xc and glycopyrronium.⁹¹ Furthermore, a study investigating the effects of bronchodilator therapy on ventilatory mechanics during exercise showed that pregnant reductions in dynamic hyperinflation and dyspnoea were paralleled by decreased respiratory muscle activity.⁷⁶

Table 2

Effect of long-acting bronchodilators on resting and dynamic lung volumes and practice measures (results are differences versus placebo unless otherwise stated)

There are few published comparisons of long-acting bronchodilators. Tiotropium was reported to exist superior to salmeterol in improving resting volumes and practice endurance,^92,93 and indacaterol was reported to be superior to salmeterol for its effect on resting inspiratory capacity.⁸³

The additive effects of combining a long-acting bronchodilator and pulmonary rehabilitation have been discussed higher up.^64,70 Because the benign effects of long-interim bronchodilators on do and associated hyperinflation are observed every bit early as day i of handling,^94–97 these agents may exist particularly useful in the context of exercise programmes to provide patients with an initial 'boost' that may help them achieve successful rehabilitation.

Combining two bronchodilators may extend the improvements seen with unmarried agents — for instance, resting IC was increased with indacaterol plus tiotropium compared with tiotropium lonely⁹⁸ or with formoterol plus tiotropium versus tiotropium alone.^99–101 The addition of tiotropium to an inhaled corticosteroid (ICS)/long-interim β₂-agonist (LABA) combination has been reported to ameliorate resting lung volumes compared with either individual component.^102–104 The bronchodilator combination of tiotropium and salmeterol was more constructive than an ICS/LABA for improving resting lung volumes in hyperinflated patients, although exercise endurance time was non significantly increased.¹⁰⁵

ICS and ICS/LABA combinations

Ii studies accept compared the effects of ICS/LABA handling with a LABA alone. O'Donnell et al. reported that fluticasone/salmeterol reduced resting and dynamic hyperinflation and increased exercise endurance time compared with placebo merely not compared with salmeterol (Table 3 and Appendix 2).¹⁰⁶ A later study with a college ICS dose constitute that adding fluticasone to long-acting bronchodilator therapy decreased EELV during practise without improvements in dyspnoea or IC.⁵⁸ The budesonide/formoterol combination was reported to increase do endurance and reduce dynamic hyperinflation compared with both placebo and formoterol.¹⁰⁷ The mechanism for an effect of ICS on hyperinflation is unclear, but may involve a direct local activeness on pulmonary cells or vasculature (e.g. vasoconstriction).^58,107 The budesonide/ formoterol combination was reported to improve resting lung volumes more than salmeterol/fluticasone,¹⁰⁸ and with a faster onset of effect.^109,110

Table three

Effect of ICS and ICS+LABA on resting and dynamic lung volumes and exercise measures (results are differences versus placebo unless otherwise stated)

Other treatments: roflumilast, theophylline, mucoactive treatment (acetylcysteine)

The oral phosphodiesterase-4 inhibitor roflumilast had no upshot on hyperinflation or exercise times compared with placebo after 12 weeks of handling.¹¹¹ Theophylline has been reported to reduce lung volumes and amend exercise endurance,^112,113 possibly through improved respiratory muscle performance likely secondary to unmeasured lung volume reduction.^114,116 Reduced hyperinflation and improved exercise endurance were reported following treatment with the mucoactive/antioxidant treatment acetylcysteine.¹¹⁷

Conclusions

While persistent and progressive expiratory flow limitation is the hallmark of COPD, its event — lung hyperinflation — importantly contributes to the exertional dyspnoea that limits activeness and prevent patients from going about their normal everyday activities. Such inactivity tin can have a detrimental result on physical conditioning and health-related quality of life. Acute increases in hyperinflation above the already increased resting level are likely to underlie the acute worsening of symptoms during increased action and during exacerbations of COPD. Reducing hyperinflation and its consequences will have important benefits for COPD patients by interrupting the savage cycle of dyspnoea, action limitation, deconditioning, and impaired health-related quality of life. Some of the common co-morbidities in COPD start early in the affliction and may be related to inactivity and physical deconditioning.^44,45 It seems logical that the before the vicious cycle is interrupted, the amend the upshot for patients, and there should be a lower threshold for initiating treatments appropriate to the stage of the illness (e.m. long-acting bronchodilators and an exercise program for patients with mild-to-moderate disease who experience persistent dyspnoea). Practise and pulmonary rehabilitation take a valuable effect at all stages of the disease.

Acknowledgments

Handling editor Anthony D'Urzo

Sarah Filcek (Circle Scientific discipline, Tytherington, Cheshire, Great britain) assisted in preparing a first draft of the manuscript that was critically reviewed and revised by the authors, but did not see the ICMJE criteria for authorship (world wide web.icmje.org/).

Funding Training of the first draft of the manuscript was funded by Novartis Pharma AG (Basel, Switzerland). The authors did not receive whatever payment for producing this paper.

Appendix 1

Appendix 2

Summary of key differences with long-interim bronchodilators, ICS, or ICS+LABA versus placebo or comparator in post-dose practice measures: (A) exercise endurance time; (B) Borg dyspnoea score; (c) inspiratory capacity (IC); and (d) tidal volume (data are presented equally mean treatment? placebo differences ±SE (solid line) or with 95% CI (dashed lines), where available; ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001). (A) †Alter from baseline in limit of do tolerance was significantly greater for FOR+TIO than FOR+PBO (124±27% vs 68±14%; p<0.05). ‡Added to bronchodilator therapy. (B) †As expected at end of exercise (i.e. when patients stopped exercising owing to symptom limitation) the level of symptoms was the same in the two handling arms. ‡Added to bronchodilator therapy. (C) †Measured at end of exercise, not isotime. ‡Added to bronchodilator therapy. (D) †Added to bronchodilator therapy. ACL=aclidinium; BUD=budesonide, FOR=formoterol, FP=fluticasone propionate, ICS=inhaled corticosteroid, IND=indacaterol, LABA=long-interim β-agonist, SLM=salmeterol, PBO=placebo, TIO=tiotropium

Footnotes

Neither MT nor any member of his close family has any shares in pharmaceutical companies. In the last 3 years he has received speaker'southward honoraria for speaking at sponsored meetings from the following companies marketing respiratory and allergy products: AstraZeneca (AZ), Boehringer Ingleheim (BI), GlaxoSmithKline (GSK), MSD, Napp, Schering-Plough, Teva. He has received honoraria for attention informational panels with Almirall, AZ, BI, Chiesi, GSK, MSD, Merck Respiratory, Schering-Plough, Teva, and Novartis. He has received sponsorship to nourish international scientific meetings from GSK, MSD, AZ, and Mundipharma and he has received funding for inquiry projects from GSK, MSD, and Napp. He held a research fellowship and is Chief Medical Advisor to Asthma UK. He is a fellow member of the UK Department of Health Asthma Strategy Group and Dwelling Oxygen Grouping. He is a member of the MHRA Respiratory and Allergy Expert Informational Group, the BTS SIGN Asthma Guideline Grouping and the EPOS Rhinosinusitis Guideline Group. MT is an Associate Editor of the PCRJ, just was not involved in the editorial review of, nor the conclusion to publish, this article.

Md has received speaker fees from AZ, GSK, Boehringer-Pfizer, and Novartis; consulting fees from AZ, Boehringer-Pfizer, Dompé, GSK, Novartis, Nycomed, and Vectura; grant support from AZ, Boehringer-Pfizer, GSK, and Chiesi. He has no stock holdings in pharmaceutical companies and has never received grant support from the tobacco industry. DEO has served on advisory boards for BI, Pfizer, GSK, Novartis and Nycomed; has received lecture fees from BI, AZ, Pfizer, and GSK; and has received manufacture-sponsored grants from: BI, GSK, Merck Frosst Canada, Novartis, and Pfizer.

References

• Buist Equally, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the Bold Study): a population-based prevalence study. Lancet 2007;370:741–50. http://dx.doi.org/10.1016/S0140-6736(07)61377-4 [PubMed] [Google Scholar]
• East of England Public Wellness Observatory. Modelled approximate of prevalence of COPD in England. http://www.apho.org.uk/resource/item.aspx?RID=111122 (accessed ix July 2022).
• Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary affliction among patients at risk in chief care. CMAJ 2010;182:673–viii. http://dx.doi.org/10.1503/cmaj.091784 [PMC complimentary article] [PubMed] [Google Scholar]
• Mannino DM, Buist AS. Global burden of COPD: take chances factors, prevalence, and future trends. Lancet 2007;370:765–73. http://dx.doi.org/10.1016/S0140-6736(07)61380-iv [PubMed] [Google Scholar]
• Garcia-Aymerich J, Serra P, I, Mannino DM, et al. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2022;66:585–90. http://dx.doi.org/ten.1136/thx.2010.152876 [PubMed] [Google Scholar]
• Jones Pow. Action limitation and quality of life in COPD. COPD 2007;4:273–8. http://dx.doi.org/10.1080/15412550701480265 [PubMed] [Google Scholar]
• O'Donnell DE, Webb KA. The major limitation to do performance in COPD is dynamic hyperinflation. J Appl Physiol 2008;105:753–5. http://dx.doi.org/10.1152/japplphysiol.90336.2008b [PubMed] [Google Scholar]
• Rennard Southward, Decramer M, Calverley PM, et al. Impact of COPD in Northward America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799–805. http://dx.doi.org/ten.1183/09031936.02.03242002 [PubMed] [Google Scholar]
• Ofir D, Laveneziana P, Webb KA, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:622–9. http://dx.doi.org/10.1164/rccm.200707-1064OC [PubMed] [Google Scholar]
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-scale-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645–53. http://dx.doi.org/10.1056/NEJMoa032158 [PubMed] [Google Scholar]
• McDonough JE, Yuan R, Suzuki M, et al. Minor-airway obstruction and emphysema in chronic obstructive pulmonary affliction. N Engl J Med 2022;365:1567–75. http://dx.doi.org/10.1056/NEJMoa1106955 [PMC costless article] [PubMed] [Google Scholar]
• O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006;61:354–61. http://dx.doi.org/10.1136/thx.2005.041830 [PMC complimentary article] [PubMed] [Google Scholar]
• Decramer Yard. Respiratory muscles in COPD: regulation of trophical condition. Verh Yard Acad Geneeskd Belg 2001;63:577–602. [PubMed] [Google Scholar]
• Decramer Thou. Pulmonary rehabilitation 2007: from bench to practice and back. Clin Invest Med 2008;31:E312–E318. [PubMed] [Google Scholar]
• Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to do limitation in COPD. Am J Respir Crit Care Med 1996;153:976–80. [PubMed] [Google Scholar]
• O'Donnell DE. Hyperinflation, dyspnea, and do intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:180–4. http://dx.doi.org/ten.1513/pats.200508-093DO [PubMed] [Google Scholar]
• McKenzie DK, Butler JE, Gandevia SC. Respiratory musculus role and activation in chronic obstructive pulmonary illness. J Appl Physiol 2009;107:621–9. http://dx.doi.org/ten.1152/japplphysiol.00163.2009 [PubMed] [Google Scholar]
• Cassart M, Pettiaux N, Gevenois PA, et al. Outcome of chronic hyperinflation on diaphragm length and surface surface area. Am J Respir Crit Care Med 1997;156:504–08. [PubMed] [Google Scholar]
• Gorman RB, McKenzie DK, Pride NB, et al. Diaphragm length during tidal breathing in patients with chronic obstructive pulmonary disease. Am J Respir Crit Intendance Med 2002;166:1461–9. http://dx.doi.org/10.1164/rccm.200111-087OC [PubMed] [Google Scholar]
• Similowski T, Yan Southward, Gauthier AP, et al. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med 1991;325:917–23. http://dx.doi.org/10.1056/NEJM199109263251304 [PubMed] [Google Scholar]
• Klimathianaki One thousand, Vaporidi K, Georgopoulos D. Respiratory musculus dysfunction in COPD: from muscles to cell. Curr Drug Targets 2022;12:478–88. http://dx.doi.org/10.2174/138945011794751474 [PubMed] [Google Scholar]
• Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005;26:420–eight. http://dx.doi.org/10.1183/09031936.05.00136304 [PubMed] [Google Scholar]
• Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary affliction. Am J Respir Crit Care Med 2005;172:1510–six. http://dx.doi.org/x.1164/rccm.200504-595OC [PubMed] [Google Scholar]
• Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224–38. http://dx.doi.org/10.1183/09031936.00109906 [PubMed] [Google Scholar]
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2022;364:1093–103. http://dx.doi.org/10.1056/NEJMoa1008378 [PubMed] [Google Scholar]
• Washko GR, Fan VS, Ramsey SD, et al. The outcome of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Intendance Med 2008;177:164–nine. http://dx.doi.org/10.1164/rccm.200708-1194OC [PMC costless article] [PubMed] [Google Scholar]
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations past salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19–26. http://dx.doi.org/x.1164/rccm.200707-973OC [PubMed] [Google Scholar]
• Coussa ML, Guerin C, Eissa NT, et al. Partitioning of piece of work of breathing in mechanically ventilated COPD patients. J Appl Physiol 1993;75:1711–19. [PubMed] [Google Scholar]
• O'Donnell DE, Ora J, Webb KA, et al. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol 2009;167:116–32. http://dx.doi.org/10.1016/j.resp.2009.01.010 [PubMed] [Google Scholar]
• Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, cess, and management of dyspnea. Am J Respir Crit Intendance Med 2022;185:435–52. http://dx.doi.org/10.1164/rccm.201111-2042ST [PMC costless article] [PubMed] [Google Scholar]
• Laveneziana P, Webb KA, Ora J, et al. Development of dyspnea during exercise in chronic obstructive pulmonary disease: bear on of critical volume constraints. Am J Respir Crit Intendance Med 2022;184:1367–73. http://dx.doi.org/10.1164/rccm.201106-1128OC [PubMed] [Google Scholar]
• O'Donnell DE, Guenette JA, Maltais F, Webb KA. Decline of resting inspiratory capacity in COPD: the bear upon on breathing design, dyspnea, and ventilatory capacity during exercise. Chest 2022;141:753–62. http://dx.doi.org/10.1378/chest.11-0787 [PubMed] [Google Scholar]
• Williams M, Cafarella P, Olds T, et al. The language of breathlessness differentiates between patients with COPD and age-matched adults. Breast 2008;134:489–96. http://dx.doi.org/10.1378/chest.07-2916 [PubMed] [Google Scholar]
• Williams M, Cafarella P, Olds T, et al. Affective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with COPD. Chest 2010;138:315–22. http://dx.doi.org/10.1378/chest.09-2498 [PubMed] [Google Scholar]
• Deesomchok A, Webb KA, Forkert Fifty, et al. Lung hyperinflation and its reversibility in patients with airway obstacle of varying severity. COPD 2010;7:428–37. http://dx.doi.org/10.3109/15412555.2010.528087 [PubMed] [Google Scholar]
• Garcia-Rio F, Lores V, Mediano O, et al. Daily physical action in patients with chronic obstructive pulmonary illness is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009;180:506–12. http://dx.doi.org/x.1164/rccm.200812-1873OC [PubMed] [Google Scholar]
• Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage thing? Breast 2010;137:1116–21. http://dx.doi.org/10.1378/breast.09-1847 [PubMed] [Google Scholar]
• Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997;337:1799–806. http://dx.doi.org/10.1056/NEJM199712183372503 [PubMed] [Google Scholar]
• Ottenheijm CA, Heunks LM, Dekhuijzen RP. Diaphragm adaptations in patients with COPD. Respir Res 2008;ix:12. http://dx.doi.org/x.1186/1465-9921-9-12 [PMC costless article] [PubMed] [Google Scholar]
• Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:972–seven. http://dx.doi.org/ten.1164/rccm.200407-855OC [PubMed] [Google Scholar]
• Shrikrishna D, Patel Yard, Tanner RJ, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2022;40:1115–22. http://dx.doi.org/10.1183/09031936.00170111 [PubMed] [Google Scholar]
• Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary illness on physical activity: a cross-exclusive study. Am J Respir Crit Care Med 2008;177:743–51. http://dx.doi.org/10.1164/rccm.200707-1011OC [PubMed] [Google Scholar]
• Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J 2009;33:262–72. http://dx.doi.org/10.1183/09031936.00024608 [PubMed] [Google Scholar]
• Decramer M, Cooper CB. Treatment of COPD: the sooner the ameliorate? Thorax 2010;65:837–41. http://dx.doi.org/x.1136/thx.2009.133355 [PubMed] [Google Scholar]
• Decramer Thou, Rennard Due south, Troosters T, et al. COPD equally a lung affliction with systemic consequences: clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235–56. http://dx.doi.org/ten.1080/15412550802237531 [PubMed] [Google Scholar]
• Malerba M, Ragnoli B, Salameh M, et al. Sub-clinical left ventricular diastolic dysfunction in early stage of chronic obstructive pulmonary affliction. J Biol Regul Homeost Agents 2022;25:443–51. [PubMed] [Google Scholar]
• Zaman 1000, Mahmood S, Altayeh A. Low inspiratory capacity to total lung chapters ratio is a risk cistron for chronic obstructive pulmonary disease exacerbation. Am J Med Sci 2010;339:411–14. [PubMed] [Google Scholar]
• Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-full lung chapters ratio predicts bloodshed in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591–seven. http://dx.doi.org/10.1164/rccm.200407-867OC [PubMed] [Google Scholar]
• Yuan R, Hogg JC, Skin PD, et al. Prediction of the rate of decline in FEV(ane) in smokers using quantitative computed tomography. Thorax 2009;64:944–9. http://dx.doi.org/x.1136/thx.2008.112433 [PMC free article] [PubMed] [Google Scholar]
• Casanova C, de Torres JP, guirre-Jaime A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2022;184:1015–21. http://dx.doi.org/x.1164/rccm.201105-0831OC [PubMed] [Google Scholar]
• Mohamed Hoesein FA, Zanen P, Boezen HM, et al. Lung function turn down in heavy male smokers relates to baseline airflow obstruction severity. Chest 2022. Jun 21 [Epub alee of print]. http://dx.doi.org/10.1378/chest.11-2837 [PubMed]
• Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in i 2nd over fourth dimension in COPD. N Engl J Med 2022;365:1184–92. http://dx.doi.org/10.1056/NEJMoa1105482 [PubMed] [Google Scholar]
• Cazzola Chiliad, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416–69. http://dx.doi.org/10.1183/09031936.00099306 [PubMed] [Google Scholar]
• Diaz O, Villafranca C, Ghezzo H, et al. Office of inspiratory capacity on practise tolerance in COPD patients with and without tidal expiratory flow limitation at balance. Eur Respir J 2000;sixteen:269–75. http://dx.doi.org/ten.1034/j.1399-3003.2000.16b14.10 [PubMed] [Google Scholar]
• Celli B, ZuWallack R, Wang Due south, Kesten S. Comeback in resting inspiratory chapters and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Breast 2003;124:1743–8. http://dx.doi.org/10.1378/chest.124.5.1743 [PubMed] [Google Scholar]
• O'Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 2006;xv:61–seven. http://dx.doi.org/10.1183/09059180.00010002 [Google Scholar]
• O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance later anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542–9. [PubMed] [Google Scholar]
• Guenette JA, Raghavan N, Harris-McAllister Five, et al. Upshot of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respir Med 2022;105:1836–45. http://dx.doi.org/x.1016/j.rmed.2011.08.021 [PubMed] [Google Scholar]
• Luo YM, Hopkinson NS, Polkey MI. Tough at the top: must end-expiratory lung volume make way for end-inspiratory lung volume? Eur Respir J 2022;40:283–v. http://dx.doi.org/10.1183/09031936.00021912 [PubMed] [Google Scholar]
• Casaburi R, Porszasz J. Reduction of hyperinflation past pharmacologic and other interventions. Proc Am Thorac Soc 2006;iii:185–9. http://dx.doi.org/x.1513/pats.200508-095DO [PubMed] [Google Scholar]
• Puente-Maestu L, Stringer WW. Hyperinflation and its direction in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:381–400. http://dx.doi.org/x.2147/copd.2006.1.4.381 [PMC free article] [PubMed] [Google Scholar]
• Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Thorax 2006;61:559–67. http://dx.doi.org/10.1136/thx.2005.053470 [PMC gratis article] [PubMed] [Google Scholar]
• Ambrosino N, Foglio One thousand, Balzano G, et al. Tiotropium and practise training in COPD patients: furnishings on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis 2008;3:771–eighty. [PMC free article] [PubMed] [Google Scholar]
• Casaburi R, Kukafka D, Cooper CB, et al. Improvement in practice tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Breast 2005;127:809–17. http://dx.doi.org/x.1378/chest.127.iii.809 [PubMed] [Google Scholar]
• Voduc Due north, Tessier C, Sabri E, et al. Effects of oxygen on exercise elapsing in chronic obstructive pulmonary disease patients before and after pulmonary rehabilitation. Can Respir J 2010;17:e14–19. [PMC free article] [PubMed] [Google Scholar]
• Casaburi R. Activity promotion: a paradigm shift for chronic obstructive pulmonary disease therapeutics. Proc Am Thorac Soc 2022;8:334–7. http://dx.doi.org/10.1513/pats.201101-001RM [PubMed] [Google Scholar]
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, direction, and prevention of chronic obstructive pulmonary disease. world wide web goldcopd com (accessed fourteen June 2022). [PubMed]
• Bellamy D, Bouchard J, Henrichsen S, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of chronic obstructive pulmonary illness (COPD). Prim Care Respir J 2006;15:48–57. http://dx.doi.org/x.1016/j.pcrj.2005.xi.003 [PMC free article] [PubMed] [Google Scholar]
• Marciniuk DD, Brooks D, Butcher Southward, et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary illness—practical issues: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2010;17:159–68. [PMC complimentary article] [PubMed] [Google Scholar]
• Nici L, Donner C, Wouters East, et al. American Thoracic Lodge/European Respiratory Society argument on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390–413. http://dx.doi.org/x.1164/rccm.200508-1211ST [PubMed] [Google Scholar]
• Puhan MA, Gimeno-Santos E, Scharplatz Chiliad, et al. Pulmonary rehabilitation post-obit exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2022;CD005305. [PubMed]
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary affliction: a clinical practice guideline update from the American Higher of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Social club. Ann Intern Med 2022;155:179–91. [PubMed] [Google Scholar]
• Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: Joint ACCP/AACVPR bear witness-based clinical practice guidelines. Breast 2007;131:4S–42S. http://dx.doi.org/10.1378/chest.06-2418 [PubMed] [Google Scholar]
• Lacasse Y, Goldstein R, Lasserson TJ, Martin South. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;CD003793. [PubMed]
• O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and practise tolerance in COPD. Eur Respir J 2004;23:832–twoscore. http://dx.doi.org/10.1183/09031936.04.00116004 [PubMed] [Google Scholar]
• Human WD, Mustfa N, Nikoletou D, et al. Event of salmeterol on respiratory muscle activeness during exercise in poorly reversible COPD. Thorax 2004;59:471–6. http://dx.doi.org/10.1136/thx.2003.019620 [PMC gratuitous article] [PubMed] [Google Scholar]
• Duranti R, Misuri G, Gorini M, et al. Mechanical loading and control of breathing in patients with severe chronic obstructive pulmonary disease. Thorax 1995;l:127–33. http://dx.doi.org/10.1136/thx.50.2.127 [PMC free article] [PubMed] [Google Scholar]
• Kyroussis D, Polkey MI, Hamnegard CH, et al. Respiratory muscle activity in patients with COPD walking to exhaustion with and without pressure level back up. Eur Respir J 2000;xv:649–55. http://dx.doi.org/10.1034/j.1399-3003.2000.15d05.ten [PubMed] [Google Scholar]
• O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007;4:145–68. http://dx.doi.org/x.1513/pats.200611-159CC [PubMed] [Google Scholar]
• Eiser North, Angus Grand, McHale South. The role of domiciliary nebulizers in managing patients with severe COPD. Respir Med 2001;95:265–74. http://dx.doi.org/x.1053/rmed.2001.1032 [PubMed] [Google Scholar]
• Shioya T, Satake 1000, Sato Yard, et al. Long-term effect of the beta2-receptor agonist procaterol on daily life performance and practice capacity in patients with stable chronic obstructive pulmonary disease. Clinical study with special reference to health-related quality of life and activities of daily living. Arzneimittelforschung 2008;58:24–viii. [PubMed] [Google Scholar]
• Thomas P, Pugsley JA, Stewart JH. Theophylline and salbutamol amend pulmonary function in patients with irreversible chronic obstructive pulmonary affliction. Chest 1992;101:160–5. http://dx.doi.org/10.1378/chest.101.one.160 [PubMed] [Google Scholar]
• Laforce C, Aumann J, de Teresa PL, et al. Sustained 24-hour efficacy of one time daily indacaterol (300 mug) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther 2022;24:162–8. http://dx.doi.org/x.1016/j.pupt.2010.06.005 [PubMed] [Google Scholar]
• Brusasco 5, Canonica GW, Dal NR, et al. Formoterol by pressurized metered-dose aerosol or dry pulverization on airway obstacle and lung hyperinflation in partially reversible COPD. J Aerosol Med Pulm Drug Deliv 2022;24:235–43. http://dx.doi.org/10.1089/jamp.2010.0862 [PubMed] [Google Scholar]
• Hanania NA, Donohue JF, Nelson H, et al. The safety and efficacy of arformoterol and formoterol in COPD. COPD 2010;7:17–31. http://dx.doi.org/10.3109/15412550903499498 [PubMed] [Google Scholar]
• Stockley RA, Chopra North, Rice L. Addition of salmeterol to existing handling in patients with COPD: a 12 month study. Thorax 2006;61:122–eight. http://dx.doi.org/10.1136/thx.2004.033266 [PMC free article] [PubMed] [Google Scholar]
• Brashier B, Dhembare P, Jantikar A, et al. Tiotropium administered past a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered past a Rotahaler in adult subjects with stable moderate-to-severe COPD. Respir Med 2007;101:2464–71. http://dx.doi.org/10.1016/j.rmed.2007.07.006 [PubMed] [Google Scholar]
• Stepanian IE, Khmel'kova NG, Belin-Atarac B. [The efficacy of tiotropium bromide (Spiriva) in the treatment of patients with chronic obstructive pulmonary illness of varying severity: results of the Russian trial]. Ter Arkh 2010;82:46–51. [PubMed] [Google Scholar]
• Tanabe Northward, Muro S, Oguma T, et al. Computed tomography assessment of pharmacological lung volume reduction induced by bronchodilators in COPD. COPD 2022;9:401–08. [PubMed] [Google Scholar]
• Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary illness. Respiration 2006;73:420–7. http://dx.doi.org/10.1159/000089655 [PubMed] [Google Scholar]
• Beeh KM, Singh D, Di SL, Drollmann A. In one case-daily NVA237 improves practice tolerance from the showtime dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2022;7:503–13. http://dx.doi.org/10.2147/COPD.S32451 [PMC costless article] [PubMed] [Google Scholar]
• Fujimoto Chiliad, Kitaguchi Y, Kanda S, et al. Comparing of efficacy of long-interim bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2022;6:219–27. http://dx.doi.org/ten.2147/COPD.S18461 [PMC free commodity] [PubMed] [Google Scholar]
• van der Vaart H, Postma DS, Grevink R, et al. Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary affliction. Int J Chron Obstruct Pulmon Dis 2022;6:229–35. http://dx.doi.org/10.2147/COPD.S17482 [PMC gratis article] [PubMed] [Google Scholar]
• Beeh KM, Wagner F, Khindri Southward, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2022;8:340–five. http://dx.doi.org/10.3109/15412555.2011.594464 [PubMed] [Google Scholar]
• O'Donnell DE, Voduc N, Fitzpatrick One thousand, Webb KA. Outcome of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary affliction. Eur Respir J 2004;24:86–94. http://dx.doi.org/10.1183/09031936.04.00072703 [PubMed] [Google Scholar]
• Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2022;105:580–7. http://dx.doi.org/10.1016/j.rmed.2010.11.019 [PubMed] [Google Scholar]
• O'Donnell DE, Casaburi R, Vincken West, et al. Outcome of indacaterol on practice endurance and lung hyperinflation in COPD. Respir Med 2022;105:1030–half-dozen. http://dx.doi.org/10.1016/j.rmed.2011.03.014 [PubMed] [Google Scholar]
• Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent utilise of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2022;67:781–8. http://dx.doi.org/x.1136/thoraxjnl-2011-201140 [PubMed] [Google Scholar]
• Hanania NA, Boota A, Kerwin E, et al. Efficacy and safety of nebulized formoterol every bit add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a half-dozen-week, randomized, placebo-controlled, clinical trial. Drugs 2009;69:1205–sixteen. http://dx.doi.org/10.2165/00003495-200969090-00005 [PubMed] [Google Scholar]
• Tashkin DP, Donohue JF, Mahler DA, et al. Furnishings of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009;103:516–24. http://dx.doi.org/10.1016/j.rmed.2008.12.014 [PubMed] [Google Scholar]
• van Noord JA, Aumann JL, Janssens Due east, et al. Furnishings of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509–17. http://dx.doi.org/10.1378/chest.129.iii.509 [PubMed] [Google Scholar]
• Perng DW, Wu CC, Su KC, et al. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology 2006;11:598–602. http://dx.doi.org/10.1111/j.1440-1843.2006.00889.x [PubMed] [Google Scholar]
• Singh D, Brooks J, Hagan Thousand, et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus private components in moderate to severe COPD. Thorax 2008;63:592–8. http://dx.doi.org/x.1136/thx.2007.087213 [PubMed] [Google Scholar]
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741–50. http://dx.doi.org/10.1164/rccm.200904-0492OC [PubMed] [Google Scholar]
• Magnussen H, Paggiaro P, Schmidt H, et al. Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med 2022;106:1413–20. http://dx.doi.org/ten.1016/j.rmed.2012.05.011 [PubMed] [Google Scholar]
• O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130:647–56. http://dx.doi.org/10.1378/chest.130.3.647 [PubMed] [Google Scholar]
• Worth H, Forster One thousand, Eriksson One thousand, et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010;104:1450–9. http://dx.doi.org/10.1016/j.rmed.2010.07.006 [PubMed] [Google Scholar]
• Tzani P, Crisafulli E, Nicolini M, et al. Furnishings of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis 2022;6:503–09. [PMC free commodity] [PubMed] [Google Scholar]
• Celli BR, Tashkin DP, Rennard SI, et al. Bronchodilator responsiveness and onset of upshot with budesonide/formoterol pMDI in COPD. Respir Med 2022;105:1176–88. http://dx.doi.org/10.1016/j.rmed.2011.02.020 [PubMed] [Google Scholar]
• Lindberg A, Szalai Z, Pullerits T, Radeczky Due east. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary affliction and reversible airway obstacle. Respirology 2007;12:732–9. http://dx.doi.org/ten.1111/j.1440-1843.2007.01132.x [PubMed] [Google Scholar]
• O'Donnell DE, Bredenbroker D, Brose Thou, Webb KA. Physiological effects of roflumilast at residuum and during practise in COPD. Eur Respir J 2022;39:1104–12. http://dx.doi.org/10.1183/09031936.00096511 [PubMed] [Google Scholar]
• Dreyse J, Silva F, Diaz O, et al. [Clinical and functional benefits of adding theophylline to a standard treatment with curt acting bronchodilators in patients with COPD]. Rev Med Chil 2005;133:1211–xix. http://dx.doi.org/10.4067/S0034-98872005001000010 [PubMed] [Google Scholar]
• Waterhouse JC, Pritchard SM, Howard P. Hyperinflation, trapped gas and theophylline in chronic obstructive pulmonary affliction. Monaldi Curvation Chest Dis 1993;48:126–nine. [PubMed] [Google Scholar]
• Murciano D, Aubier M, Lecocguic Y, Pariente R. Furnishings of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984;311:349–53. http://dx.doi.org/10.1056/NEJM198408093110601 [PubMed] [Google Scholar]
• Travers J, Laveneziana P, Webb KA, et al. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med 2007;101:2017–24. [PubMed] [Google Scholar]
• Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with astringent chronic obstructive pulmonary disease. N Engl J Med 1989;320:1521–v. http://dx.doi.org/10.1056/NEJM198906083202304 [PubMed] [Google Scholar]
• Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Breast 2009;136:381–6. http://dx.doi.org/10.1378/breast.09-0421 [PubMed] [Google Scholar]
• Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited practice operation over 8 h with in one case-daily tiotropium in patients with COPD. Chest 2005;128:1168–78. http://dx.doi.org/10.1378/chest.128.3.1168 [PubMed] [Google Scholar]
• Berton DC, Reis K, Siqueira AC, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010;104:1288–96. http://dx.doi.org/10.1016/j.rmed.2010.05.017 [PubMed] [Google Scholar]
• Neder JA, Fuld JP, Overend T, et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med 2007;101:2056–64. http://dx.doi.org/10.1016/j.rmed.2007.06.006 [PubMed] [Google Scholar]

---

Articles from Primary Care Respiratory Journal: Periodical of the Full general Practice Airways Group are provided here courtesy of Primary Intendance Respiratory Gild U.k./Macmillan Publishers Limited

---

Can You Repair Hyper Inflamed Lungs?,

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442765/

Posted by: yatesthfulted.blogspot.com

Share this post